Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to 234.98%.

  • Janux Therapeutics' EBITDA Margin rose 40046600.0% to 234.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 1051.64%, marking a year-over-year decrease of 6567400.0%. This contributed to the annual value of 637.48% for FY2024, which is 564900.0% up from last year.
  • According to the latest figures from Q3 2025, Janux Therapeutics' EBITDA Margin is 234.98%, which was up 40046600.0% from 4239.64% recorded in Q3 2024.
  • Over the past 5 years, Janux Therapeutics' EBITDA Margin peaked at 79.25% during Q2 2024, and registered a low of 4239.64% during Q3 2024.
  • For the 5-year period, Janux Therapeutics' EBITDA Margin averaged around 1000.5%, with its median value being 831.01% (2023).
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -37754700bps in 2024, then skyrocketed by 40046600bps in 2025.
  • Over the past 5 years, Janux Therapeutics' EBITDA Margin (Quarter) stood at 848.39% in 2021, then soared by 37bps to 538.59% in 2022, then grew by 25bps to 403.01% in 2023, then tumbled by -952bps to 4239.64% in 2024, then skyrocketed by 94bps to 234.98% in 2025.
  • Its last three reported values are 234.98% in Q3 2025, 4239.64% for Q3 2024, and 79.25% during Q2 2024.